Reported Standalone quarterly numbers for AstraZeneca Pharma are:Net Sales at Rs 387.52 crore in June 2024 up 31.16% from Rs. 295.47 crore in June 2023.
Quarterly Net Loss at Rs. 11.79 crore in June 2024 down 121.89% from Rs. 53.86 crore in June 2023.
EBITDA stands at Rs. 46.43 crore in June 2024 down 38.38% from Rs. 75.35 crore in June 2023.
| AstraZeneca shares closed at 6,535.55 on August 12, 2024 (NSE) and has given 20.92% returns over the last 6 months and 65.09% over the last 12 months. |
| AstraZeneca Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 387.52 | 383.20 | 295.47 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 387.52 | 383.20 | 295.47 | | EXPENDITURE | | Consumption of Raw Materials | 45.85 | 33.62 | 19.08 | | Purchase of Traded Goods | 240.33 | 74.98 | 102.85 | | Increase/Decrease in Stocks | -55.74 | 104.95 | -11.34 | | Power & Fuel | -- | -- | -- | | Employees Cost | 60.96 | 57.98 | 54.97 | | Depreciation | 3.91 | 3.76 | 3.80 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 58.04 | 62.28 | 62.66 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 34.17 | 45.62 | 63.45 | | Other Income | 8.35 | 8.66 | 8.10 | | P/L Before Int., Excpt. Items & Tax | 42.52 | 54.29 | 71.55 | | Interest | 0.11 | -0.07 | 0.15 | | P/L Before Exceptional Items & Tax | 42.41 | 54.35 | 71.40 | | Exceptional Items | -57.56 | -- | -- | | P/L Before Tax | -15.16 | 54.35 | 71.40 | | Tax | -3.37 | 14.88 | 17.54 | | P/L After Tax from Ordinary Activities | -11.79 | 39.48 | 53.86 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -11.79 | 39.48 | 53.86 | | Equity Share Capital | 5.00 | 5.00 | 5.00 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -4.72 | 15.79 | 21.54 | | Diluted EPS | -4.72 | 15.79 | 21.54 | | EPS After Extra Ordinary | | Basic EPS | -4.72 | 15.79 | 21.54 | | Diluted EPS | -4.72 | 15.79 | 21.54 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
